AI-Powered wearables could warn of heart attacks before they happen
NCT ID NCT07496931
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to create a risk prediction model for acute myocardial infarction (heart attack) using artificial intelligence and wearable devices. Researchers will enroll 3,000 high-risk patients in the Beijing area and collect data from ECGs and other sources. The goal is to enable early warning and faster treatment, potentially reducing heart-related deaths.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Acute Myocardial Infarction Risk Prediction Model (diagnostic test using AI and wearable devices)
- What this could lead to
- If successful, this could lead to a tool that predicts heart attacks early, helping patients seek care sooner and reducing deaths.
- What could go wrong
- This is an early-stage model-building study, not yet testing a treatment. The model may not work as expected in real-world settings or may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The integrated team covers preliminary cohorts with multi-dimensional data, including multi-center clinical, imaging, and sample information (total cases \>300,000). Based on cohort quality and risk factors, multi-dimensional data is collected on high-risk patients (such as those with previous myocardial infarction, multi-vessel disease, CKD, DM, etc.) to complete the data. The primary endpoint is the time to the first occurrence of acute myocardial infarction within one year after enrollment. Follow-up points are set according to myocardial reinfarction characteristics and needs, and a long-term follow-up plan is formulated (including: frequency of follow-up, follow-up methods, laboratory tests, wearable device data, etc.). Regular follow-up and supplementation of multi-modal data are conducted, ultimately completing a 3,000-case multi-dimensional AMI cohort.
- Ages
-
18 to 85 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. High-risk population for acute myocardial infarction, previously confirmed by cardiac imaging to have coronary artery disease and at least one of the following risk factors: * Multivessel coronary artery disease (defined as ≥50% stenosis in at least 2 coronary artery regions, including the left main coronary artery) * Previous myocardial infarction * Patients with diabetes currently undergoing glucose-lowering treatment * Chronic kidney disease (CKD) defined as an estimated glomerular filtration rate \<60 mL/min/1.73 m² with a known history of chronic kidney disease or biomarkers indicating chronic kidney damage * Peripheral artery disease, defined as any of the following: ankle-brachial index \<0.85; \>50% stenosis in lower limb arteries confirmed by angiography (invasive or non-invasive) or duplex ultrasound; limb amputation, peripheral artery bypass, or vascular surgery (such as angioplasty or endarterectomy) secondary to ischemia 2. Age ≥18 years 3. Ability to understand and comply with the study protocol and sign the informed consent form Exclusion Criteria: 1. Researchers consider diseases or conditions that are not suitable for participation in this study (such as mental illness, significant cognitive impairment, neurodegenerative diseases, advanced malignant tumors) or situations (such as inability to communicate well with researchers in the local language, unwillingness to comply with study procedures/instructions, inability to understand study-specific training, physically fragile and vulnerable subjects). 2. Participation in a clinical trial involving drugs or devices within 3 months prior to enrollment. 3. Women who are pregnant, planning to become pregnant, or breastfeeding. 4. Known life-threatening diseases with an expected survival of less than 12 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A temporary wire that keeps hearts beating on cue
- AI may spot deadly heart rhythms before they strike
- Antioxidant infusion may shield the heart from reperfusion injury
- Can a temporary heart pump save more lives in cardiogenic shock?
- Can a Community-Based rehab program boost heart recovery after a first attack?
- AI on a simple ECG: a new way to gauge heart attack severity?